<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 12 Mar 2021 11:26:40 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>进击的疫苗新秀，落寞的巨头</title><link>https://mp.weixin.qq.com/s/qE0S9lpTQZx7771G17djFA</link><description></description><content:encoded><![CDATA[进击的疫苗新秀，落寞的巨头]]></content:encoded><pubDate>Fri, 12 Mar 2021 08:26:00 +0800</pubDate></item><item><title>康诺亚IL-4R呼吸适应症授权石药，CM326哮喘获批临床</title><link>https://mp.weixin.qq.com/s/_I2FSLdXQrfeJwuUcp31vg</link><description></description><content:encoded><![CDATA[康诺亚IL-4R呼吸适应症授权石药，CM326哮喘获批临床]]></content:encoded><pubDate>Fri, 12 Mar 2021 08:26:00 +0800</pubDate></item><item><title>媲美mRNA疫苗：Novavax三聚体蛋白疫苗有效率96.4%</title><link>https://mp.weixin.qq.com/s/rHm3w8vd1myNjk7ntd1jGA</link><description></description><content:encoded><![CDATA[媲美mRNA疫苗：Novavax三聚体蛋白疫苗有效率96.4%]]></content:encoded><pubDate>Fri, 12 Mar 2021 08:26:00 +0800</pubDate></item><item><title>国内首个：恒瑞医药Aβ抗体获批临床，治疗阿尔茨海默症</title><link>https://mp.weixin.qq.com/s/Ohd7Ua5I8zABTZd7dTKtRw</link><description></description><content:encoded><![CDATA[国内首个：恒瑞医药Aβ抗体获批临床，治疗阿尔茨海默症]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item><item><title>天境生物引进穿膜抗体技术：Alphabody</title><link>https://mp.weixin.qq.com/s/4bDBOvXF2AZnZr_C_7jeiw</link><description></description><content:encoded><![CDATA[天境生物引进穿膜抗体技术：Alphabody]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item><item><title>CD3双抗靶向TCR，治疗T细胞淋巴瘤</title><link>https://mp.weixin.qq.com/s/_-Qw46mEWvmUUAECRGiqIg</link><description></description><content:encoded><![CDATA[CD3双抗靶向TCR，治疗T细胞淋巴瘤]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item><item><title>2020年降糖药畅销排行榜</title><link>https://mp.weixin.qq.com/s/Y-P9lH6KVYI5aYNihuIzRg</link><description></description><content:encoded><![CDATA[2020年降糖药畅销排行榜]]></content:encoded><pubDate>Thu, 11 Mar 2021 08:58:25 +0800</pubDate></item><item><title>2020年全球糖尿病市场研究报告</title><link>https://mp.weixin.qq.com/s/q1QGFie3wF1DWJIwvHpNOQ</link><description></description><content:encoded><![CDATA[2020年全球糖尿病市场研究报告]]></content:encoded><pubDate>Wed, 10 Mar 2021 11:49:00 +0800</pubDate></item><item><title>泰它西普获批，疗效怎么样</title><link>https://mp.weixin.qq.com/s/Oy9zuAN8JHsQ0Bus--2kTA</link><description></description><content:encoded><![CDATA[泰它西普获批，疗效怎么样]]></content:encoded><pubDate>Wed, 10 Mar 2021 11:49:00 +0800</pubDate></item><item><title>石药集团2亿元入股倍而达，获得三代EGFR-TKI</title><link>https://mp.weixin.qq.com/s/L9eJKRavJWf2L5SUbMTkvg</link><description></description><content:encoded><![CDATA[石药集团2亿元入股倍而达，获得三代EGFR-TKI]]></content:encoded><pubDate>Wed, 10 Mar 2021 11:49:00 +0800</pubDate></item><item><title>IL-36R二期临床失败，AnaptysBio股价大跌36%</title><link>https://mp.weixin.qq.com/s/-Y_Dm050AuNwbT6m_WDtaA</link><description></description><content:encoded><![CDATA[IL-36R二期临床失败，AnaptysBio股价大跌36%]]></content:encoded><pubDate>Tue, 09 Mar 2021 07:23:13 +0800</pubDate></item><item><title>Silverback新型ADC</title><link>https://mp.weixin.qq.com/s/R8DnD7ZRYg0_eCGQcWS8Yw</link><description></description><content:encoded><![CDATA[Silverback新型ADC]]></content:encoded><pubDate>Tue, 09 Mar 2021 07:23:13 +0800</pubDate></item><item><title>CureVac与特斯拉合作开发mRNA“打印机”</title><link>https://mp.weixin.qq.com/s/mKcHQ0GlrRWwipdkHCQ9gw</link><description></description><content:encoded><![CDATA[CureVac与特斯拉合作开发mRNA“打印机”]]></content:encoded><pubDate>Tue, 09 Mar 2021 07:23:13 +0800</pubDate></item><item><title>阿斯利康Imfinzi之后，罗氏Tecentriq也撤回尿路上皮癌适应症</title><link>https://mp.weixin.qq.com/s/MIp3P9pBW_oIh8hnKsStSA</link><description></description><content:encoded><![CDATA[阿斯利康Imfinzi之后，罗氏Tecentriq也撤回尿路上皮癌适应症]]></content:encoded><pubDate>Tue, 09 Mar 2021 07:23:13 +0800</pubDate></item><item><title>新冠南非和英国突变株，对多数中和抗体产生抵抗</title><link>https://mp.weixin.qq.com/s/PpHTpL14QB4lG-eF4y5JhQ</link><description></description><content:encoded><![CDATA[新冠南非和英国突变株，对多数中和抗体产生抵抗]]></content:encoded><pubDate>Tue, 09 Mar 2021 07:23:13 +0800</pubDate></item><item><title>中国ADC技术全梳理</title><link>https://mp.weixin.qq.com/s/l_gusNEy6FQQc4IpjuesWg</link><description></description><content:encoded><![CDATA[中国ADC技术全梳理]]></content:encoded><pubDate>Mon, 08 Mar 2021 11:32:12 +0800</pubDate></item><item><title>Moderna启动南非突变株新冠疫苗的临床试验</title><link>https://mp.weixin.qq.com/s/7Jl9mSRdpATtuA5R_5zUyQ</link><description></description><content:encoded><![CDATA[Moderna启动南非突变株新冠疫苗的临床试验]]></content:encoded><pubDate>Sun, 07 Mar 2021 07:55:39 +0800</pubDate></item><item><title>肿瘤免疫治疗的炎症性副作用</title><link>https://mp.weixin.qq.com/s/UmDorgB-0M0CQulLvzRA2Q</link><description></description><content:encoded><![CDATA[肿瘤免疫治疗的炎症性副作用]]></content:encoded><pubDate>Sat, 06 Mar 2021 14:34:34 +0800</pubDate></item><item><title>国内第2家：百奥赛图申报CD40抗体</title><link>https://mp.weixin.qq.com/s/N5jtL6T2hxJ7BlrasScmHQ</link><description></description><content:encoded><![CDATA[国内第2家：百奥赛图申报CD40抗体]]></content:encoded><pubDate>Sat, 06 Mar 2021 14:34:34 +0800</pubDate></item><item><title>双抗：靶向肿瘤新抗原</title><link>https://mp.weixin.qq.com/s/x1rl305jarNVsLMvfzSutA</link><description></description><content:encoded><![CDATA[双抗：靶向肿瘤新抗原]]></content:encoded><pubDate>Fri, 05 Mar 2021 22:33:50 +0800</pubDate></item></channel></rss>